FDA inspection
Raybow (Suzhou) Pharmaceutical Co., Ltd.: FDA inspection ending May 22, 2025
FDA inspection 1273595 · No Action Indicated (NAI) · Suzhou
Key facts
| Inspection ID | 1273595 |
|---|---|
| Firm | Raybow (Suzhou) Pharmaceutical Co., Ltd. |
| FEI number | 3007114474 |
| Address | No. 18 Tonglian Road, Bixi Xinqu Changshu |
| City | Suzhou |
| Country | China |
| Fiscal year | 2025 |
| Inspection end date | May 22, 2025 |
| Classification | No Action Indicated (NAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- No Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data